Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide in Non-Muscle Invasive Bladder Cancer
NCT05521698Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bicalutamide in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Average Epidermal Growth Factor Receptor (EGFR) expression level at 28 days. Started Jun 2026; status: recruiting.
02
Drugs
bicalutamide
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05521698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521698.